Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

p27 transcriptionally coregulates cJun to drive programs of tumor progression.

Yoon H, Kim M, Jang K, Shin M, Besser A, Xiao X, Zhao D, Wander SA, Briegel K, Morey L, Minn A, Slingerland JM.

Proc Natl Acad Sci U S A. 2019 Apr 2;116(14):7005-7014. doi: 10.1073/pnas.1817415116. Epub 2019 Mar 15.

2.

Dual Src and MEK Inhibition Decreases Ovarian Cancer Growth and Targets Tumor Initiating Stem-Like Cells.

Simpkins F, Jang K, Yoon H, Hew KE, Kim M, Azzam DJ, Sun J, Zhao D, Ince TA, Liu W, Guo W, Wei Z, Zhang G, Mills GB, Slingerland JM.

Clin Cancer Res. 2018 Oct 1;24(19):4874-4886. doi: 10.1158/1078-0432.CCR-17-3697. Epub 2018 Jun 29.

PMID:
29959144
3.

Vitamin C promotes apoptosis in breast cancer cells by increasing TRAIL expression.

Sant DW, Mustafi S, Gustafson CB, Chen J, Slingerland JM, Wang G.

Sci Rep. 2018 Mar 28;8(1):5306. doi: 10.1038/s41598-018-23714-7.

4.

Obesity and adverse breast cancer risk and outcome: Mechanistic insights and strategies for intervention.

Picon-Ruiz M, Morata-Tarifa C, Valle-Goffin JJ, Friedman ER, Slingerland JM.

CA Cancer J Clin. 2017 Sep;67(5):378-397. doi: 10.3322/caac.21405. Epub 2017 Aug 1. Review.

5.

VEGFA links self-renewal and metastasis by inducing Sox2 to repress miR-452, driving Slug.

Kim M, Jang K, Miller P, Picon-Ruiz M, Yeasky TM, El-Ashry D, Slingerland JM.

Oncogene. 2017 Sep 7;36(36):5199-5211. doi: 10.1038/onc.2017.4. Epub 2017 May 15.

6.

p16 loss rescues functional decline of Brca1-deficient mammary stem cells.

Scott A, Bai F, Chan HL, Liu S, Slingerland JM, Robbins DJ, Capobianco AJ, Pei XH.

Cell Cycle. 2017 Apr 18;16(8):759-764. doi: 10.1080/15384101.2017.1295185. Epub 2017 Feb 22.

7.

VEGFA activates an epigenetic pathway upregulating ovarian cancer-initiating cells.

Jang K, Kim M, Gilbert CA, Simpkins F, Ince TA, Slingerland JM.

EMBO Mol Med. 2017 Mar;9(3):304-318. doi: 10.15252/emmm.201606840.

8.

p16INK4a suppresses BRCA1-deficient mammary tumorigenesis.

Scott A, Bai F, Chan HL, Liu S, Ma J, Slingerland JM, Robbins DJ, Capobianco AJ, Pei XH.

Oncotarget. 2016 Dec 20;7(51):84496-84507. doi: 10.18632/oncotarget.13015.

9.

Targeting of RAGE-ligand signaling impairs breast cancer cell invasion and metastasis.

Kwak T, Drews-Elger K, Ergonul A, Miller PC, Braley A, Hwang GH, Zhao D, Besser A, Yamamoto Y, Yamamoto H, El-Ashry D, Slingerland JM, Lippman ME, Hudson BI.

Oncogene. 2017 Mar;36(11):1559-1572. doi: 10.1038/onc.2016.324. Epub 2016 Sep 26.

PMID:
27669433
10.

Erratum to: PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy.

Wander SA, Zhao D, Besser AH, Hong F, Wei J, Ince TA, Milikowski C, Bishopric NH, Minn AJ, Creighton CJ, Slingerland JM.

Breast Cancer Res Treat. 2016 Apr;156(2):405-6. doi: 10.1007/s10549-016-3752-9.

11.

Interactions between Adipocytes and Breast Cancer Cells Stimulate Cytokine Production and Drive Src/Sox2/miR-302b-Mediated Malignant Progression.

Picon-Ruiz M, Pan C, Drews-Elger K, Jang K, Besser AH, Zhao D, Morata-Tarifa C, Kim M, Ince TA, Azzam DJ, Wander SA, Wang B, Ergonul B, Datar RH, Cote RJ, Howard GA, El-Ashry D, Torné-Poyatos P, Marchal JA, Slingerland JM.

Cancer Res. 2016 Jan 15;76(2):491-504. doi: 10.1158/0008-5472.CAN-15-0927. Epub 2016 Jan 7.

12.

MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer.

Hew KE, Miller PC, El-Ashry D, Sun J, Besser AH, Ince TA, Gu M, Wei Z, Zhang G, Brafford P, Gao W, Lu Y, Mills GB, Slingerland JM, Simpkins F.

Clin Cancer Res. 2016 Feb 15;22(4):935-47. doi: 10.1158/1078-0432.CCR-15-0534. Epub 2015 Oct 19.

13.

VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2.

Zhao D, Pan C, Sun J, Gilbert C, Drews-Elger K, Azzam DJ, Picon-Ruiz M, Kim M, Ullmer W, El-Ashry D, Creighton CJ, Slingerland JM.

Oncogene. 2015 Jun 11;34(24):3107-19. doi: 10.1038/onc.2014.257. Epub 2014 Aug 25.

PMID:
25151964
14.

Primary breast tumor-derived cellular models: characterization of tumorigenic, metastatic, and cancer-associated fibroblasts in dissociated tumor (DT) cultures.

Drews-Elger K, Brinkman JA, Miller P, Shah SH, Harrell JC, da Silva TG, Ao Z, Schlater A, Azzam DJ, Diehl K, Thomas D, Slingerland JM, Perou CM, Lippman ME, El-Ashry D.

Breast Cancer Res Treat. 2014 Apr;144(3):503-17. doi: 10.1007/s10549-014-2887-9. Epub 2014 Feb 25.

PMID:
24567196
15.

Links between oestrogen receptor activation and proteolysis: relevance to hormone-regulated cancer therapy.

Zhou W, Slingerland JM.

Nat Rev Cancer. 2014 Jan;14(1):26-38. Review. Erratum in: Nat Rev Cancer. 2014 Feb;14(2):146.

PMID:
24505618
16.

Triple negative breast cancer initiating cell subsets differ in functional and molecular characteristics and in γ-secretase inhibitor drug responses.

Azzam DJ, Zhao D, Sun J, Minn AJ, Ranganathan P, Drews-Elger K, Han X, Picon-Ruiz M, Gilbert CA, Wander SA, Capobianco AJ, El-Ashry D, Slingerland JM.

EMBO Mol Med. 2013 Oct;5(10):1502-22. doi: 10.1002/emmm.201302558. Epub 2013 Aug 27.

17.

ERα, SKP2 and E2F-1 form a feed forward loop driving late ERα targets and G1 cell cycle progression.

Zhou W, Srinivasan S, Nawaz Z, Slingerland JM.

Oncogene. 2014 May 1;33(18):2341-53. doi: 10.1038/onc.2013.197. Epub 2013 Jun 17.

PMID:
23770852
18.

PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy.

Wander SA, Zhao D, Besser AH, Hong F, Wei J, Ince TA, Milikowski C, Bishopric NH, Minn AJ, Creighton CJ, Slingerland JM.

Breast Cancer Res Treat. 2013 Apr;138(2):369-81. doi: 10.1007/s10549-012-2389-6. Epub 2013 Feb 21. Erratum in: Breast Cancer Res Treat. 2016 Apr;156(2):405-6.

19.

Cytokines, obesity, and cancer: new insights on mechanisms linking obesity to cancer risk and progression.

Gilbert CA, Slingerland JM.

Annu Rev Med. 2013;64:45-57. doi: 10.1146/annurev-med-121211-091527. Epub 2012 Oct 26. Review.

PMID:
23121183
20.

Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo.

Simpkins F, Hevia-Paez P, Sun J, Ullmer W, Gilbert CA, da Silva T, Pedram A, Levin ER, Reis IM, Rabinovich B, Azzam D, Xu XX, Ince TA, Yang JY, Verhaak RG, Lu Y, Mills GB, Slingerland JM.

Clin Cancer Res. 2012 Nov 1;18(21):5911-23. doi: 10.1158/1078-0432.CCR-12-1257. Epub 2012 Aug 15.

21.

ERα phosphorylation at Y537 by Src triggers E6-AP-ERα binding, ERα ubiquitylation, promoter occupancy, and target gene expression.

Sun J, Zhou W, Kaliappan K, Nawaz Z, Slingerland JM.

Mol Endocrinol. 2012 Sep;26(9):1567-77. doi: 10.1210/me.2012-1140. Epub 2012 Aug 3.

22.

Promotion of cytoplasmic mislocalization of p27 by Helicobacter pylori in gastric cancer.

Wen S, So Y, Singh K, Slingerland JM, Resnick MB, Zhang S, Ruiz V, Moss SF.

Oncogene. 2012 Apr 5;31(14):1771-80. doi: 10.1038/onc.2011.362. Epub 2011 Aug 15.

23.

The physiology of integrated nuclear and extranuclear steroid signaling: introductory comments.

Hammes SR, Kelly MJ, Slingerland JM.

Steroids. 2011 Aug;76(9):821. doi: 10.1016/j.steroids.2011.05.006. Epub 2011 May 30. No abstract available.

PMID:
21645536
24.

Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy.

Wander SA, Hennessy BT, Slingerland JM.

J Clin Invest. 2011 Apr;121(4):1231-41. doi: 10.1172/JCI44145. Epub 2011 Apr 1. Review.

25.

p27: a barometer of signaling deregulation and potential predictor of response to targeted therapies.

Wander SA, Zhao D, Slingerland JM.

Clin Cancer Res. 2011 Jan 1;17(1):12-8. doi: 10.1158/1078-0432.CCR-10-0752. Epub 2010 Oct 21. Review.

26.

Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo.

Chen Y, Alvarez EA, Azzam D, Wander SA, Guggisberg N, Jordà M, Ju Z, Hennessy BT, Slingerland JM.

Breast Cancer Res Treat. 2011 Jul;128(1):69-78. doi: 10.1007/s10549-010-1024-7. Epub 2010 Jul 29.

PMID:
20669046
27.

p27 as Jekyll and Hyde: regulation of cell cycle and cell motility.

Larrea MD, Wander SA, Slingerland JM.

Cell Cycle. 2009 Nov 1;8(21):3455-61. Epub 2009 Nov 11.

PMID:
19829074
28.

RSK1 drives p27Kip1 phosphorylation at T198 to promote RhoA inhibition and increase cell motility.

Larrea MD, Hong F, Wander SA, da Silva TG, Helfman D, Lannigan D, Smith JA, Slingerland JM.

Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9268-73. doi: 10.1073/pnas.0805057106. Epub 2009 May 22.

29.

Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors.

Chen Y, Guggisberg N, Jorda M, Gonzalez-Angulo A, Hennessy B, Mills GB, Tan CK, Slingerland JM.

Clin Cancer Res. 2009 May 15;15(10):3396-405. doi: 10.1158/1078-0432.CCR-08-3127.

30.

Phosphorylation of p27Kip1 regulates assembly and activation of cyclin D1-Cdk4.

Larrea MD, Liang J, Da Silva T, Hong F, Shao SH, Han K, Dumont D, Slingerland JM.

Mol Cell Biol. 2008 Oct;28(20):6462-72. doi: 10.1128/MCB.02300-07. Epub 2008 Aug 18.

31.

mTOR-raptor binds and activates SGK1 to regulate p27 phosphorylation.

Hong F, Larrea MD, Doughty C, Kwiatkowski DJ, Squillace R, Slingerland JM.

Mol Cell. 2008 Jun 20;30(6):701-11. doi: 10.1016/j.molcel.2008.04.027.

32.

The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy.

Chu IM, Hengst L, Slingerland JM.

Nat Rev Cancer. 2008 Apr;8(4):253-67. doi: 10.1038/nrc2347. Review.

PMID:
18354415
33.

Long-range activation of GREB1 by estrogen receptor via three distal consensus estrogen-responsive elements in breast cancer cells.

Sun J, Nawaz Z, Slingerland JM.

Mol Endocrinol. 2007 Nov;21(11):2651-62. Epub 2007 Jul 31.

PMID:
17666587
34.

Src promotes estrogen-dependent estrogen receptor alpha proteolysis in human breast cancer.

Chu I, Arnaout A, Loiseau S, Sun J, Seth A, McMahon C, Chun K, Hennessy B, Mills GB, Nawaz Z, Slingerland JM.

J Clin Invest. 2007 Aug;117(8):2205-15.

35.

The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis.

Liang J, Shao SH, Xu ZX, Hennessy B, Ding Z, Larrea M, Kondo S, Dumont DJ, Gutterman JU, Walker CL, Slingerland JM, Mills GB.

Nat Cell Biol. 2007 Feb;9(2):218-24. Epub 2007 Jan 21.

PMID:
17237771
36.

Tamoxifen may prevent both ER+ and ER- breast cancers and select for ER- carcinogenesis: an alternative hypothesis.

Esserman LJ, Ozanne EM, Dowsett M, Slingerland JM.

Breast Cancer Res. 2005;7(6):R1153-8. Epub 2005 Nov 21.

37.

Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression.

Liang J, Slingerland JM.

Cell Cycle. 2003 Jul-Aug;2(4):339-45. Review.

PMID:
12851486
38.

CRM1/Ran-mediated nuclear export of p27(Kip1) involves a nuclear export signal and links p27 export and proteolysis.

Connor MK, Kotchetkov R, Cariou S, Resch A, Lupetti R, Beniston RG, Melchior F, Hengst L, Slingerland JM.

Mol Biol Cell. 2003 Jan;14(1):201-13.

39.

PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest.

Liang J, Zubovitz J, Petrocelli T, Kotchetkov R, Connor MK, Han K, Lee JH, Ciarallo S, Catzavelos C, Beniston R, Franssen E, Slingerland JM.

Nat Med. 2002 Oct;8(10):1153-60. Epub 2002 Sep 16.

PMID:
12244302
40.

Non-malignant and tumor-derived cells differ in their requirement for p27Kip1 in transforming growth factor-beta-mediated G1 arrest.

Donovan JC, Rothenstein JM, Slingerland JM.

J Biol Chem. 2002 Nov 1;277(44):41686-92. Epub 2002 Aug 28.

41.

Altered p27(Kip1) phosphorylation, localization, and function in human epithelial cells resistant to transforming growth factor beta-mediated G(1) arrest.

Ciarallo S, Subramaniam V, Hung W, Lee JH, Kotchetkov R, Sandhu C, Milic A, Slingerland JM.

Mol Cell Biol. 2002 May;22(9):2993-3002.

42.

PTEN deficiency: a role in mammary carcinogenesis.

Petrocelli T, Slingerland JM.

Breast Cancer Res. 2001;3(6):356-60. Epub 2001 Oct 1. Review.

43.

Constitutive MEK/MAPK activation leads to p27(Kip1) deregulation and antiestrogen resistance in human breast cancer cells.

Donovan JC, Milic A, Slingerland JM.

J Biol Chem. 2001 Nov 2;276(44):40888-95. Epub 2001 Aug 29.

44.

Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells.

Cariou S, Donovan JC, Flanagan WM, Milic A, Bhattacharya N, Slingerland JM.

Proc Natl Acad Sci U S A. 2000 Aug 1;97(16):9042-6.

45.

Prognostic implications of expression of the cell cycle inhibitor protein p27Kip1.

Cariou S, Catzavelos C, Slingerland JM.

Breast Cancer Res Treat. 1998;52(1-3):29-41. Review.

PMID:
10066070
46.

Interleukin-6 dependent induction of the cyclin dependent kinase inhibitor p21WAF1/CIP1 is lost during progression of human malignant melanoma.

Flørenes VA, Lu C, Bhattacharya N, Rak J, Sheehan C, Slingerland JM, Kerbel RS.

Oncogene. 1999 Jan 28;18(4):1023-32.

47.

Reduced expression of the cell cycle inhibitor p27Kip1 in non-small cell lung carcinoma: a prognostic factor independent of Ras.

Catzavelos C, Tsao MS, DeBoer G, Bhattacharya N, Shepherd FA, Slingerland JM.

Cancer Res. 1999 Feb 1;59(3):684-8.

48.

Cyclin E2: a novel CDK2 partner in the late G1 and S phases of the mammalian cell cycle.

Lauper N, Beck AR, Cariou S, Richman L, Hofmann K, Reith W, Slingerland JM, Amati B.

Oncogene. 1998 Nov 19;17(20):2637-43.

49.

E-Cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27(KIP1).

St Croix B, Sheehan C, Rak JW, Flørenes VA, Slingerland JM, Kerbel RS.

J Cell Biol. 1998 Jul 27;142(2):557-71.

50.

Protein expression of the cell-cycle inhibitor p27Kip1 in malignant melanoma: inverse correlation with disease-free survival.

Flørenes VA, Maelandsmo GM, Kerbel RS, Slingerland JM, Nesland JM, Holm R.

Am J Pathol. 1998 Jul;153(1):305-12.

Supplemental Content

Loading ...
Support Center